SlideShare a Scribd company logo
1 of 1
A systematic review and meta-analysis: the effect of TSH suppressive
therapy on relapse rate on Graves’ disease treated patients
Gold Ekeanyanwu and Audrey Mercer
Department of Pharmacology, 29-39 Brunswick Square, London WC1N 1AX, UK
UCL SCHOOL OF PHARMACY
BRUNSWICK SQUARE
Introduction
Method
Results
Conclusion
Graves’ disease is an autoimmune disorder caused by the
presence of specific antibodies stimulating the thyroid gland to
release an excess of thyroid hormones.
Figure 3. “Risk of bias summary”: authors’ judgements about
each risk of bias item for each included study. + meaning the
adequate, - meaning inadequate, and ? meaning unclear.
43 of records identified
through database searching
0 additional trials was
identified through other sources
18 records after duplicates were removed
18 records screened
5 records excluded
11 full text articles
assessed for eligibility
3 full text articles excluded
For not having the same
dose of ATD in both
groups
8 studies included in
qualitative analysis
8 studies included in
quantitative analysis
(meta-analysis)
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow chart
of the literature search.Figure 1. Preferred Reporting Items for
Systematic Reviews and Meta-Analysis
flow chart of the literature search.
Studyname Statistics for each study Odds ratio and 95% CI
Odds Lower Upper T4 Relative Relative
ratio limit limit Z-Value p-Value Treated Control weight weight
Glinoer et al (2001) 0.519 0.209 1.288 -1.415 0.157 23/ 42 28/ 40 22.97
Hashizumeet al (1991) 0.032 0.004 0.251 -3.274 0.001 1/ 60 17/ 49 9.53
Hoermannet al (2002) 0.672 0.374 1.206 -1.334 0.182 28/ 115 36/ 111 28.69
Mastorakos et a(2003)l 2.103 0.364 12.140 0.831 0.406 4/ 8 5/ 15 11.93
Rittmaster et al (1998) 0.978 0.492 1.945 -0.062 0.951 57/ 98 30/ 51 26.89
0.600 0.284 1.267 -1.339 0.180
0.01 0.1 1 10 100
Favours A Favours B
MetaAnalysis
Meta Analysis
Evaluation copy
Figure 4. Forest plot of 5 studies, comparing relapse between T4 treated group and control, Each study is represented with a square the
size of the square is proportional to the precision of the study. Studies were weighted by the inverse of the variance of their measure of effect
in that larger studies make higher contribution to the overall estimated result. The horizontal line drawn around each square was used
to represent the 95% confidence interval of that study. The aggregated Odds Ratio (0.600) of all studies is represented as a diamond at
the bottom with 95% CI, There was no statistically significant difference in rate of relapse between the T4 treated group and the
control (OR, 0.600; p=0.180)
Model Studyname Statistics for each study Relapsed / Total Odds ratio and 95%CI
Odds Lower Upper T3
ratio limit limit Z-Value p-Value treated Control
Wolfganget al(2000) 1.085 0.429 2.745 0.172 0.863 14/31 18/44
Pujolet al(1997) 1.338 0.386 4.637 0.459 0.646 12/19 13/23
Mastorakos et al(2003) 0.500 0.085 2.952 -0.765 0.444 2/ 12 5/ 15
Fixed 1.030 0.519 2.046 0.085 0.932
0.01 0.1 1 10 100
Favours A Favours B
Meta Analysis
Meta Analysis
Evaluation copy
Figure 5. Forest plot of 3 studies, comparing relapse between T3 treated group and control, The combined OR;1.030; 95% CI, 0.519-
2.416; ) of all 3 study is represented as a diamond at the bottom with 95% CI, There was no difference observed between the two
groups (OR, p=0.9322)
Study name Statistics for each study Sample size Hedges's g and 95% CI
Hedges's Standard Lower Upper TSH
g error Variance limit limit Z-Value p-ValueSuppressedControl
McLveretal(1996) 0.246 0.270 0.073 -0.283 0.776 0.912 0.362 25 29
Mastorakosetal(2003) -0.978 0.242 0.059 -1.452 -0.503 -4.039 0.000 38 37
Rittmasteretal(1998) 2.982 0.244 0.059 2.504 3.459 12.240 0.000 98 51
0.776 0.145 0.021 0.492 1.060 5.353 0.000
-4.00 -2.00 0.00 2.00 4.00
Favours A Favours B
MetaAnalysis
MetaAnalysis
Evaluation copy
Figure 6. Data was pooled from 3 studies for the mean time of relapse between the two groups. There was no statistical difference in
the time taken to relapse between the TSH suppressed group and the control, standard difference in mean (hedges’s g) was 0.750;
95% CI, -1.617-3.118; p=0.534.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper
ratio limit limit Z-Value p-Value
Glinoer et al 2000 32.143 3.747 275.750 3.164 0.002
Wilson et al (1990) 46.143 19.361 109.973 8.647 0.000
Docter et al (1986) 1.125 0.158 7.986 0.118 0.906
Mukrakami et al (1988) 36.186 1.821 719.085 2.353 0.019
McGregor et al (1980) 26.632 3.280 216.200 3.072 0.002
Takata et al (1980) 26.667 2.309 308.000 2.630 0.009
Zakranja et al (1980) 96.429 4.515 2059.526 2.925 0.003
Romaldini et al (1981) 2.885 0.954 8.720 1.877 0.061
Schleusener et al (1989) 2.589 1.699 3.945 4.428 0.000
Bliddal et al (1981) 4.278 0.798 22.928 1.697 0.090
Teng et al (1988) 10.286 2.565 41.240 3.290 0.001
deBruin et al (1988) 3.852 0.403 36.784 1.171 0.241
Young et al (1988) 2.407 0.831 6.976 1.618 0.106
Madec et al (1984) 5.029 1.575 16.055 2.727 0.006
Allanic et al (1990) 2.857 1.218 6.703 2.413 0.016
Wener et al (1991) 10.400 2.643 40.920 3.351 0.001
Weetman et al 0.958 0.323 2.841 -0.077 0.939
6.263 3.367 11.647 5.795 0.000
0.01 0.1 1 10 100
Favours A Favours B
Meta Analysis
Meta Analysis
Figure 7. Relapse between TR-ab positive patient and TR-ab negative patient at the end of ATD therapy, A previous meta-analysis (Feldt-
Rasmussen et al, 1994) was found during the search of references, their result was combined with one additional trial from this present
study. A total of 17 studies was pooled to obtain the effect of positive antibodies in the serum of patients after initial successful ATD
therapy. The rate of relapse was significantly higher in the TR-ab positive patient compared with patient with a negative TR-ab.
(OR, 6.932; 95% CI, 3.713-12.942; p=0.00)
-5 -4 -3 -2 -1 0 1 2 3 4 5
0.0
0.5
1.0
1.5
2.0
StandardError
Log odds ratio
Funnel Plot of Standard Error byLog odds ratio
Figure 8. Funnel plot of TR-ab as a predictor of relapse. This display
the studies included in this meta-analysis as a plot of effect size against
sample size (or some other measure of the extent to which the findings
could be affected by the play of chance). Because studies with a small
sample size have more chance variability than larger studies, the
expected picture is one of a symmetrical inverted funnel if the plot is
asymmetric, it indicates the presence of publication bias, meaning
that the meta-analysis may have not included all available trials.
• To investigate whether the suppression of TSH with
exogenous thyroid hormones (T4 & T3) reduce the odds of
relapse after successful treatment with ATD.
Aims
• Effect of Smoking on relapse rate
• Presence of tyrotropin receptor antibodies at the end of initial
treatment (ATD therapy) as a predictor of relapse
Secondary outcome measures
Intervention
Patients were treated with anti-thyroid drugs (20-60𝜇𝑔 of
methimazole or equivalent) until serum thyroid hormone
concentrations are within the corresponding reference ranges. They
were given thyroxine, tri-iodothyronin (50-100𝜇𝑔), if necessary, to
suppress serum TSH to undetectable concentrations (i.e. less than
0.04 mU/1) or a placebo.
• A meta-analysis was used to combine the
results of independent clinical trials to
obtain a quantitative estimate of the overall
effect of TSH suppressive therapy. This is
presented in the form of a forest plot. A
random effect model was used.
• Search database : Cochrane , PubMed,
EMBASE, Google scholar and HighWire
press. MeSH terms: “Graves' disease,”
“Thyroxine,” “Recurrence,” “Antithyroid
drugs,”
• Inclusion criteria: Randomised and Non-
randomised controlled trials; patients must
be initially made euthyroid with ATD; Same
dose of ATD used for both groups.
• A funnel plot was used to explore the risk of
publication bias
The data-analysis was carried out using Comprehensive meta-analysis software version 3.3.070 2014. , (2a) The program uses a
spreadsheet for data entry, but requires the user to identify specific columns to hold the study names and the effect size data. allows the
user to select the class of data entry types, the list of formats are arranged hierarchically. (2b) White columns are used for entering data.
Yellow columns display the computed effect size, This values are used in generating the plot, Depending on the nature of the study, the
result will be represented differently, (2c) Run analysis to generate the forest plot. The comparison between the two groups was performed
using odds ratio (OR) (The ratio of the odds of an event in one group (intervention group) to the odds of an event in another (e.g. the
control group)), with corresponding 95% confidence interval [CI], a random effect model is used. A p value <0.05 was considered
statistically significant.
(2a) (2b)
(2c)
• Prolonged administration of exogenous thyroid hormone to suppress
TSH level, does reduces the rate of recurrence of hyperthyroidism,
however this was not shown to be statically significant
• Presence of TR-ab in the serum after successful treatment with ATD
was the only parameter shown to reduce long term remission
Favours TSH Favours control
suppression
Favours T4 Favours control
Favours T3 Favours control
Favours TR-ab- Favours TR-ab+
Symptoms
Goitre high level of thyroid hormones
(T4) and (T3)
NervousnessHeat intolerance
TremorGraves’ opthalmopathy
(eyelid retraction)
Reference
1) Glinoer D, de Nayer P and Bex M (2001) Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144(5): 475-483.
2) Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M and Nagasawa T (1991) Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324(14): 947-953.
3) Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H and Mann K (2002) Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 12(12): 1119-1128.
4) Mastorakos G, Doufas AG, Mantzos E, Mantzos J and Koutras DA (2003) T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy. J Endocrinol Invest 26(10): 979-984.

More Related Content

What's hot

Semi‑quantitative analysis cerebrospinal fluid chemistry and cellularity using
Semi‑quantitative analysis cerebrospinal fluid chemistry and cellularity usingSemi‑quantitative analysis cerebrospinal fluid chemistry and cellularity using
Semi‑quantitative analysis cerebrospinal fluid chemistry and cellularity usingNeurologyKota
 
Quantitative Statistical Analysis Work Sample From Statswork
Quantitative Statistical Analysis Work Sample From StatsworkQuantitative Statistical Analysis Work Sample From Statswork
Quantitative Statistical Analysis Work Sample From StatsworkStats Statswork
 
Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...
Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...
Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...Aalap Shah
 
Modelling differential clustering and treatment effect heterogeneity in paral...
Modelling differential clustering and treatment effect heterogeneity in paral...Modelling differential clustering and treatment effect heterogeneity in paral...
Modelling differential clustering and treatment effect heterogeneity in paral...Karla hemming
 
EMW Distribution for Human Hormone
EMW Distribution for Human HormoneEMW Distribution for Human Hormone
EMW Distribution for Human HormoneIJERA Editor
 
Stopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trialStopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trialRamachandra Barik
 
Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...
Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...
Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...Rodrigo Vargas Zapana
 
PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...
PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...
PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...MatiaAhmed
 
ASBMT online journal club 6.4.15 #BMTOJC
ASBMT online journal club 6.4.15 #BMTOJCASBMT online journal club 6.4.15 #BMTOJC
ASBMT online journal club 6.4.15 #BMTOJCMiguel-Angel Perales MD
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...cambridgeWD
 
Nuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analyses
Nuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analysesNuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analyses
Nuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analysesOARSI
 
astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...
astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...
astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...LucyPi1
 
pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl...
 pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl... pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl...
pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl...Soobiya Majeed
 
DUAL ANTIPLATELET THERAPY IN STROKE
DUAL ANTIPLATELET THERAPY IN STROKEDUAL ANTIPLATELET THERAPY IN STROKE
DUAL ANTIPLATELET THERAPY IN STROKEarnab ghosh
 

What's hot (20)

Semi‑quantitative analysis cerebrospinal fluid chemistry and cellularity using
Semi‑quantitative analysis cerebrospinal fluid chemistry and cellularity usingSemi‑quantitative analysis cerebrospinal fluid chemistry and cellularity using
Semi‑quantitative analysis cerebrospinal fluid chemistry and cellularity using
 
Quantitative Statistical Analysis Work Sample From Statswork
Quantitative Statistical Analysis Work Sample From StatsworkQuantitative Statistical Analysis Work Sample From Statswork
Quantitative Statistical Analysis Work Sample From Statswork
 
Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...
Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...
Excerise Tolerance and Post-Operative Outcomes in Patients with Pulmonary Hyp...
 
Bio 152 Paper
Bio 152 PaperBio 152 Paper
Bio 152 Paper
 
Modelling differential clustering and treatment effect heterogeneity in paral...
Modelling differential clustering and treatment effect heterogeneity in paral...Modelling differential clustering and treatment effect heterogeneity in paral...
Modelling differential clustering and treatment effect heterogeneity in paral...
 
EMW Distribution for Human Hormone
EMW Distribution for Human HormoneEMW Distribution for Human Hormone
EMW Distribution for Human Hormone
 
Tdf
TdfTdf
Tdf
 
Jc2
Jc2Jc2
Jc2
 
Stopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trialStopdapt 2 randomized clinical trial
Stopdapt 2 randomized clinical trial
 
Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...
Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...
Benefits os Statins in Elderly Subjects Without Established Cardiovascular Di...
 
PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...
PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...
PEFR and FEF25_7' in Female Hypothyroids and Their Relationships with Serum T...
 
ASBMT online journal club 6.4.15 #BMTOJC
ASBMT online journal club 6.4.15 #BMTOJCASBMT online journal club 6.4.15 #BMTOJC
ASBMT online journal club 6.4.15 #BMTOJC
 
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
Clinical Trials Versus Health Outcomes Research: SAS/STAT Versus SAS Enterpri...
 
Research Report
Research ReportResearch Report
Research Report
 
paper 4
paper 4paper 4
paper 4
 
Nuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analyses
Nuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analysesNuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analyses
Nuts & Bolts of Systematic Reviews, Meta-analyses & Network Meta-analyses
 
astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...
astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...
astragalus injection as an adjuvant treatment for colorectal cancer: a meta-a...
 
pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl...
 pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl... pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl...
pharmacokinetic and pharmacodynamic interactions between Atorvastatin and Gl...
 
Resuscitation update by Professor Peter Morley
Resuscitation update by Professor Peter MorleyResuscitation update by Professor Peter Morley
Resuscitation update by Professor Peter Morley
 
DUAL ANTIPLATELET THERAPY IN STROKE
DUAL ANTIPLATELET THERAPY IN STROKEDUAL ANTIPLATELET THERAPY IN STROKE
DUAL ANTIPLATELET THERAPY IN STROKE
 

Similar to Ekeanyanwu_Gold

Exemestane Versus Tamoxifen
Exemestane Versus TamoxifenExemestane Versus Tamoxifen
Exemestane Versus Tamoxifenfondas vakalis
 
slides Testing of hypothesis.pptx
slides Testing  of  hypothesis.pptxslides Testing  of  hypothesis.pptx
slides Testing of hypothesis.pptxssuser504dda
 
An exploratory analysis of the crash 2 rct
An exploratory analysis of the crash 2 rctAn exploratory analysis of the crash 2 rct
An exploratory analysis of the crash 2 rctnswhems
 
The health effects of eating contaminated fish
The health effects of eating contaminated fishThe health effects of eating contaminated fish
The health effects of eating contaminated fishService_supportAssignment
 
When & How do Patients Change? Wolfgang Lutz Outcome Presentation
When & How do Patients Change? Wolfgang Lutz Outcome PresentationWhen & How do Patients Change? Wolfgang Lutz Outcome Presentation
When & How do Patients Change? Wolfgang Lutz Outcome PresentationScott Miller
 
Categorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.pptCategorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.pptqkmaiu
 
Inferential statistics
Inferential statisticsInferential statistics
Inferential statisticsAshok Kulkarni
 
Renal Artery Denervation Patient Selection and Results
Renal Artery Denervation Patient Selection and ResultsRenal Artery Denervation Patient Selection and Results
Renal Artery Denervation Patient Selection and ResultsPAIRS WEB
 
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...European School of Oncology
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...European School of Oncology
 
CCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptx
CCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptxCCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptx
CCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptxDoQuyenPhan1
 
Palumbo auto hsct in multiple myeloma n engl j med 2014
Palumbo auto hsct in multiple myeloma n engl j med 2014Palumbo auto hsct in multiple myeloma n engl j med 2014
Palumbo auto hsct in multiple myeloma n engl j med 2014Chandan K Das
 
INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS
INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS
INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS Paul George
 
Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...
Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...
Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...MatiaAhmed
 
Metanalysis Lecture
Metanalysis LectureMetanalysis Lecture
Metanalysis Lecturedrmomusa
 

Similar to Ekeanyanwu_Gold (20)

Quantitative Synthesis I
Quantitative Synthesis IQuantitative Synthesis I
Quantitative Synthesis I
 
Exemestane Versus Tamoxifen
Exemestane Versus TamoxifenExemestane Versus Tamoxifen
Exemestane Versus Tamoxifen
 
slides Testing of hypothesis.pptx
slides Testing  of  hypothesis.pptxslides Testing  of  hypothesis.pptx
slides Testing of hypothesis.pptx
 
An exploratory analysis of the crash 2 rct
An exploratory analysis of the crash 2 rctAn exploratory analysis of the crash 2 rct
An exploratory analysis of the crash 2 rct
 
The health effects of eating contaminated fish
The health effects of eating contaminated fishThe health effects of eating contaminated fish
The health effects of eating contaminated fish
 
When & How do Patients Change? Wolfgang Lutz Outcome Presentation
When & How do Patients Change? Wolfgang Lutz Outcome PresentationWhen & How do Patients Change? Wolfgang Lutz Outcome Presentation
When & How do Patients Change? Wolfgang Lutz Outcome Presentation
 
Categorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.pptCategorical-data-afghvvghgfhg.analysis.ppt
Categorical-data-afghvvghgfhg.analysis.ppt
 
Inferential statistics
Inferential statisticsInferential statistics
Inferential statistics
 
Renal Artery Denervation Patient Selection and Results
Renal Artery Denervation Patient Selection and ResultsRenal Artery Denervation Patient Selection and Results
Renal Artery Denervation Patient Selection and Results
 
2.1 adj cht cufer
2.1 adj cht cufer2.1 adj cht cufer
2.1 adj cht cufer
 
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
BALKAN MCO 2011 - T. Cufer - Chemotherapy: when, why, prognostic factors, reg...
 
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
Gene Profiling in Clinical Oncology - Slide 11 - J. Albanell Mestres - The Sp...
 
CCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptx
CCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptxCCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptx
CCO_HER2_Breast_Cancer_Updates_Downloadable_1.pptx
 
Palumbo auto hsct in multiple myeloma n engl j med 2014
Palumbo auto hsct in multiple myeloma n engl j med 2014Palumbo auto hsct in multiple myeloma n engl j med 2014
Palumbo auto hsct in multiple myeloma n engl j med 2014
 
What’s New With HER2?
What’s New With HER2?What’s New With HER2?
What’s New With HER2?
 
INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS
INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS
INDUCTION CHEMOTHERAPY WITH TPF IN HEAD & NECK CANCERS
 
Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...
Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...
Assessment of Cardiac Autonomic Nerve Function Status by Heart Rate Variabili...
 
Redox
RedoxRedox
Redox
 
Parametric Test.pptx
Parametric Test.pptxParametric Test.pptx
Parametric Test.pptx
 
Metanalysis Lecture
Metanalysis LectureMetanalysis Lecture
Metanalysis Lecture
 

Ekeanyanwu_Gold

  • 1. A systematic review and meta-analysis: the effect of TSH suppressive therapy on relapse rate on Graves’ disease treated patients Gold Ekeanyanwu and Audrey Mercer Department of Pharmacology, 29-39 Brunswick Square, London WC1N 1AX, UK UCL SCHOOL OF PHARMACY BRUNSWICK SQUARE Introduction Method Results Conclusion Graves’ disease is an autoimmune disorder caused by the presence of specific antibodies stimulating the thyroid gland to release an excess of thyroid hormones. Figure 3. “Risk of bias summary”: authors’ judgements about each risk of bias item for each included study. + meaning the adequate, - meaning inadequate, and ? meaning unclear. 43 of records identified through database searching 0 additional trials was identified through other sources 18 records after duplicates were removed 18 records screened 5 records excluded 11 full text articles assessed for eligibility 3 full text articles excluded For not having the same dose of ATD in both groups 8 studies included in qualitative analysis 8 studies included in quantitative analysis (meta-analysis) Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow chart of the literature search.Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis flow chart of the literature search. Studyname Statistics for each study Odds ratio and 95% CI Odds Lower Upper T4 Relative Relative ratio limit limit Z-Value p-Value Treated Control weight weight Glinoer et al (2001) 0.519 0.209 1.288 -1.415 0.157 23/ 42 28/ 40 22.97 Hashizumeet al (1991) 0.032 0.004 0.251 -3.274 0.001 1/ 60 17/ 49 9.53 Hoermannet al (2002) 0.672 0.374 1.206 -1.334 0.182 28/ 115 36/ 111 28.69 Mastorakos et a(2003)l 2.103 0.364 12.140 0.831 0.406 4/ 8 5/ 15 11.93 Rittmaster et al (1998) 0.978 0.492 1.945 -0.062 0.951 57/ 98 30/ 51 26.89 0.600 0.284 1.267 -1.339 0.180 0.01 0.1 1 10 100 Favours A Favours B MetaAnalysis Meta Analysis Evaluation copy Figure 4. Forest plot of 5 studies, comparing relapse between T4 treated group and control, Each study is represented with a square the size of the square is proportional to the precision of the study. Studies were weighted by the inverse of the variance of their measure of effect in that larger studies make higher contribution to the overall estimated result. The horizontal line drawn around each square was used to represent the 95% confidence interval of that study. The aggregated Odds Ratio (0.600) of all studies is represented as a diamond at the bottom with 95% CI, There was no statistically significant difference in rate of relapse between the T4 treated group and the control (OR, 0.600; p=0.180) Model Studyname Statistics for each study Relapsed / Total Odds ratio and 95%CI Odds Lower Upper T3 ratio limit limit Z-Value p-Value treated Control Wolfganget al(2000) 1.085 0.429 2.745 0.172 0.863 14/31 18/44 Pujolet al(1997) 1.338 0.386 4.637 0.459 0.646 12/19 13/23 Mastorakos et al(2003) 0.500 0.085 2.952 -0.765 0.444 2/ 12 5/ 15 Fixed 1.030 0.519 2.046 0.085 0.932 0.01 0.1 1 10 100 Favours A Favours B Meta Analysis Meta Analysis Evaluation copy Figure 5. Forest plot of 3 studies, comparing relapse between T3 treated group and control, The combined OR;1.030; 95% CI, 0.519- 2.416; ) of all 3 study is represented as a diamond at the bottom with 95% CI, There was no difference observed between the two groups (OR, p=0.9322) Study name Statistics for each study Sample size Hedges's g and 95% CI Hedges's Standard Lower Upper TSH g error Variance limit limit Z-Value p-ValueSuppressedControl McLveretal(1996) 0.246 0.270 0.073 -0.283 0.776 0.912 0.362 25 29 Mastorakosetal(2003) -0.978 0.242 0.059 -1.452 -0.503 -4.039 0.000 38 37 Rittmasteretal(1998) 2.982 0.244 0.059 2.504 3.459 12.240 0.000 98 51 0.776 0.145 0.021 0.492 1.060 5.353 0.000 -4.00 -2.00 0.00 2.00 4.00 Favours A Favours B MetaAnalysis MetaAnalysis Evaluation copy Figure 6. Data was pooled from 3 studies for the mean time of relapse between the two groups. There was no statistical difference in the time taken to relapse between the TSH suppressed group and the control, standard difference in mean (hedges’s g) was 0.750; 95% CI, -1.617-3.118; p=0.534. Study name Statistics for each study Odds ratio and 95% CI Odds Lower Upper ratio limit limit Z-Value p-Value Glinoer et al 2000 32.143 3.747 275.750 3.164 0.002 Wilson et al (1990) 46.143 19.361 109.973 8.647 0.000 Docter et al (1986) 1.125 0.158 7.986 0.118 0.906 Mukrakami et al (1988) 36.186 1.821 719.085 2.353 0.019 McGregor et al (1980) 26.632 3.280 216.200 3.072 0.002 Takata et al (1980) 26.667 2.309 308.000 2.630 0.009 Zakranja et al (1980) 96.429 4.515 2059.526 2.925 0.003 Romaldini et al (1981) 2.885 0.954 8.720 1.877 0.061 Schleusener et al (1989) 2.589 1.699 3.945 4.428 0.000 Bliddal et al (1981) 4.278 0.798 22.928 1.697 0.090 Teng et al (1988) 10.286 2.565 41.240 3.290 0.001 deBruin et al (1988) 3.852 0.403 36.784 1.171 0.241 Young et al (1988) 2.407 0.831 6.976 1.618 0.106 Madec et al (1984) 5.029 1.575 16.055 2.727 0.006 Allanic et al (1990) 2.857 1.218 6.703 2.413 0.016 Wener et al (1991) 10.400 2.643 40.920 3.351 0.001 Weetman et al 0.958 0.323 2.841 -0.077 0.939 6.263 3.367 11.647 5.795 0.000 0.01 0.1 1 10 100 Favours A Favours B Meta Analysis Meta Analysis Figure 7. Relapse between TR-ab positive patient and TR-ab negative patient at the end of ATD therapy, A previous meta-analysis (Feldt- Rasmussen et al, 1994) was found during the search of references, their result was combined with one additional trial from this present study. A total of 17 studies was pooled to obtain the effect of positive antibodies in the serum of patients after initial successful ATD therapy. The rate of relapse was significantly higher in the TR-ab positive patient compared with patient with a negative TR-ab. (OR, 6.932; 95% CI, 3.713-12.942; p=0.00) -5 -4 -3 -2 -1 0 1 2 3 4 5 0.0 0.5 1.0 1.5 2.0 StandardError Log odds ratio Funnel Plot of Standard Error byLog odds ratio Figure 8. Funnel plot of TR-ab as a predictor of relapse. This display the studies included in this meta-analysis as a plot of effect size against sample size (or some other measure of the extent to which the findings could be affected by the play of chance). Because studies with a small sample size have more chance variability than larger studies, the expected picture is one of a symmetrical inverted funnel if the plot is asymmetric, it indicates the presence of publication bias, meaning that the meta-analysis may have not included all available trials. • To investigate whether the suppression of TSH with exogenous thyroid hormones (T4 & T3) reduce the odds of relapse after successful treatment with ATD. Aims • Effect of Smoking on relapse rate • Presence of tyrotropin receptor antibodies at the end of initial treatment (ATD therapy) as a predictor of relapse Secondary outcome measures Intervention Patients were treated with anti-thyroid drugs (20-60𝜇𝑔 of methimazole or equivalent) until serum thyroid hormone concentrations are within the corresponding reference ranges. They were given thyroxine, tri-iodothyronin (50-100𝜇𝑔), if necessary, to suppress serum TSH to undetectable concentrations (i.e. less than 0.04 mU/1) or a placebo. • A meta-analysis was used to combine the results of independent clinical trials to obtain a quantitative estimate of the overall effect of TSH suppressive therapy. This is presented in the form of a forest plot. A random effect model was used. • Search database : Cochrane , PubMed, EMBASE, Google scholar and HighWire press. MeSH terms: “Graves' disease,” “Thyroxine,” “Recurrence,” “Antithyroid drugs,” • Inclusion criteria: Randomised and Non- randomised controlled trials; patients must be initially made euthyroid with ATD; Same dose of ATD used for both groups. • A funnel plot was used to explore the risk of publication bias The data-analysis was carried out using Comprehensive meta-analysis software version 3.3.070 2014. , (2a) The program uses a spreadsheet for data entry, but requires the user to identify specific columns to hold the study names and the effect size data. allows the user to select the class of data entry types, the list of formats are arranged hierarchically. (2b) White columns are used for entering data. Yellow columns display the computed effect size, This values are used in generating the plot, Depending on the nature of the study, the result will be represented differently, (2c) Run analysis to generate the forest plot. The comparison between the two groups was performed using odds ratio (OR) (The ratio of the odds of an event in one group (intervention group) to the odds of an event in another (e.g. the control group)), with corresponding 95% confidence interval [CI], a random effect model is used. A p value <0.05 was considered statistically significant. (2a) (2b) (2c) • Prolonged administration of exogenous thyroid hormone to suppress TSH level, does reduces the rate of recurrence of hyperthyroidism, however this was not shown to be statically significant • Presence of TR-ab in the serum after successful treatment with ATD was the only parameter shown to reduce long term remission Favours TSH Favours control suppression Favours T4 Favours control Favours T3 Favours control Favours TR-ab- Favours TR-ab+ Symptoms Goitre high level of thyroid hormones (T4) and (T3) NervousnessHeat intolerance TremorGraves’ opthalmopathy (eyelid retraction) Reference 1) Glinoer D, de Nayer P and Bex M (2001) Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144(5): 475-483. 2) Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M and Nagasawa T (1991) Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 324(14): 947-953. 3) Hoermann R, Quadbeck B, Roggenbuck U, Szabolcs I, Pfeilschifter J, Meng W, Reschke K, Hackenberg K, Dettmann J, Prehn B, Hirche H and Mann K (2002) Relapse of Graves' disease after successful outcome of antithyroid drug therapy: results of a prospective randomized study on the use of levothyroxine. Thyroid 12(12): 1119-1128. 4) Mastorakos G, Doufas AG, Mantzos E, Mantzos J and Koutras DA (2003) T4 but not T3 administration is associated with increased recurrence of Graves' disease after successful medical therapy. J Endocrinol Invest 26(10): 979-984.